Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy al...

Full description

Bibliographic Details
Main Authors: Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D Eaton, Jeffrey Thomas Yorio, Davey B Daniel, Keith C Bible, Ashish V Chintakuntlawar, Mouhammed Amir Habra
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000668.full

Internet

https://jitc.bmj.com/content/8/2/e000668.full

Similar Items